A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

ClinicalTrials.gov ID: NCT06897930

Public ClinicalTrials.gov record NCT06897930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

Study identification

NCT ID: NCT06897930
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Lupus Erythematosus, Systemic

Interventions

AZD0120 Biological
Cyclophosphamide Drug
Fludarabine Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 20, 2025
Primary completion: Apr 30, 2029
Completion: Apr 30, 2029
Last update posted: Aug 11, 2026

2025 – 2029

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	San Francisco	California	94143	Not yet recruiting
Research Site	Stanford	California	94304-2201	Not yet recruiting
Research Site	Tampa	Florida	33612	Suspended
Research Site	Atlanta	Georgia	30322	Not yet recruiting
Research Site	Chicago	Illinois	60611	Not yet recruiting
Research Site	Baltimore	Maryland	21287	Not yet recruiting
Research Site	Bethesda	Maryland	20892	Withdrawn
Research Site	Boston	Massachusetts	02115	Recruiting
Research Site	St Louis	Missouri	63110	Recruiting
Research Site	New York	New York	10032	Recruiting
Research Site	Syracuse	New York	13202-2240	Recruiting
Research Site	Chapel Hill	North Carolina	27599-7280	Recruiting
Research Site	Charlotte	North Carolina	28204	Recruiting
Research Site	Richmond	Virginia	23298	Not yet recruiting
Research Site	Seattle	Washington	98104	Recruiting
Research Site	Seattle	Washington	98195	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06897930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06897930 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →